About Inteliquet
Inteliquet is a Healthcare company based in Dover (United States) founded in 2010. Clinical trial management and analytics services for pharmaceuticals are provided. Inteliquet has raised $14.6 million across 2 funding rounds from investors including Arsenal Capital Partners and Arsenal Capital Management. Inteliquet offers products and services including OncWeb. Its focus areas include HealthTech, Life Sciences Tech, Research & Development and Clinical Trials. Its competitors include Deep Lens, EmergingMed and Wild Type Advocates; 2 of its 3 listed competitors have raised funding.
Company details
Inteliquet was founded in 2010 and is based in Dover, United States. Operations focus on the pharmaceutical sector, where clinical trial solutions are delivered to support data analysis, patient matching to studies, trial design, and predictive analytics generation. Consulting services are also extended to enhance market research for pharmaceutical clients.
- Headquarters Dover, United States
- SectorsHealthcare
- Email••••••••
- Website inteliquet.com
- Social LinkedIn X Facebook
- Total Equity Funding$14.6M (USD)
in 2 rounds
- Latest Funding Round$7.3M (USD), Series A
Aug 2014
- InvestorsArsenal Capital Partners
& 1 more
Products & Services of Inteliquet
Inteliquet offers a comprehensive portfolio of products and services, including OncWeb.
AI tool for clinical trial feasibility and patient matching
Funding Insights of Inteliquet
Inteliquet has successfully raised a total of $14.6M across 2 strategic funding rounds. The most recent funding activity was a Series A round of $7.3 million completed in August 2014. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $14.6M
- Total Rounds 2
- Last Round Series A — $7.3M
- First Round $7.3M
(Aug 2014)
- Investors Count 2
All 2 funding rounds of Inteliquet with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Aug 2014 | $7.3M | Series A | – | Arsenal Capital Partners | – |
| Aug 2014 | $7.3M | Series A | – | – |
2 investors in total: 2 institutional.
Investors in Inteliquet
Inteliquet has secured backing from 2 investors, including venture fund investors. Prominent investors backing the company include Arsenal Capital Partners and Arsenal Capital Management.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Private equity investments target specialty industrials and healthcare sectors. | 2000 | arsenalcapital.com | New York, United States | |
| acm-stl.com |
Investor details for Inteliquet
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Inteliquet
14 people are tracked at Inteliquet (7 in leadership, 7 in team).
| Name | Role | Group |
|---|---|---|
Jean Roberson | CFO | Leadership |
Linda S. Andrews | Director, Clinical Services | Leadership |
Jim Reddy | VP, Customer Engagement | Leadership |
Nate Sanders | Director of Finance, Treasurer | Leadership |
Jean Robertson | CFO | Leadership |
Robert Robbins | VP, Sales | Leadership |
Judy Woods | Associate Director, Clinical Operations, Cancer Center Support Services | Leadership |
Kevin Krenitsky | Strategic Advisor | Team |
Jonathan Lyon | Senior Quality Assurance Tester, Real World Evidence | Team |
Evan Rothfield | Sr. Software Engineer | Team |
Maria Célia Sanches Oliveira Luz | Virtual Representative | Team |
Ccrp Kevin Tillman | Business System Analyst | Team |
Dustin Bunta | Sr Software Engineer | Team |
Michele Beuck-French | Senior Database Engineer | Team |
Complete people profiles for Inteliquet
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Inteliquet
3 dated milestones of Inteliquet across 4 years, from founding to its latest funding, stage changes and deals.
- Founded Inteliquet is founded.
- Funding First funding round of $7.3M.
- Funding Latest funding round, Series A, of $7.3M.
Competitors of Inteliquet
Inteliquet has 3 listed competitors in our database, 2 of them funded. They include Deep Lens, EmergingMed and Wild Type Advocates.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| deeplens.ai | 2017 | Columbus, United States | $17.2M | AI and cloud-based digital pathology platform is developed. | ||
| emergingmed.com | 2000 | Durham, United States | $3M | Cloud based platform to match patients with clinical trials. | ||
| wildtypeadvocates.com | 2022 | United States | Wild Type Advocates provides AI-based medical information and comprehensive solutions for oncology care. |
Detailed competitors of Inteliquet
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Life Sciences Platforms & Tools
3 companies that operate in the same segment as Inteliquet (Life Sciences Platforms & Tools) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Medidata is recognized as a leading provider of SaaS solutions for clinical research. | 1999 | New York, New York, United States | USD 41.5 M | |||
AI-based solutions for health management are provided. | 2015 | Dallas, Texas, United States | USD 2.8 B | 1,111 | ||
Real-world health data is provided for research and decisions. | 2012 | Menlo Park, California, United States | USD 259.16 M |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Inteliquet
Complete news archive for Inteliquet
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Inteliquet
Inteliquet was founded in 2010 and raised its 1st funding round 4 years after it was founded.
Inteliquet is headquartered in Dover, United States. It is registered at Dover, Delaware, United States.
Inteliquet is a funded company, having raised a total of $14.6M across 2 funding rounds to date. The company's 1st funding round was a Series A of $7.3M, raised on Aug 2014.
Inteliquet was founded in 2010 and is based in Dover, United States. Operations focus on the pharmaceutical sector, where clinical trial solutions are delivered to support data analysis, patient matching to studies, trial design, and predictive analytics generation. Consulting services are also extended to enhance market research for pharmaceutical clients.
Inteliquet's top competitors include Deep Lens, EmergingMed and Wild Type Advocates.
Inteliquet offers OncWeb.
Inteliquet has 2 investors. Key investors include Arsenal Capital Partners, and Arsenal Capital Management.